Innoviva (INVA) Tops Q3 Earnings Estimates

Impact · against what's priced in

Innoviva's mixed Q3 results are marginally negative. While the company beat earnings estimates, the revenue miss and a significant 53.7% year-over-year decline in EPS signal deteriorating fundamental momentum.

INVA−0.10

No priced-in read yet

In context

A marginal EPS beat of $0.50 versus $0.49 is offset by a 6.89% revenue miss and a substantial year-over-year earnings drop from $1.08 to $0.50.

Read from the article alone

Actual

• pharmaceuticals
• earnings
• biotech
• INVA
• earnings beat
• revenue miss

Search tags